サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433551

アトピー性皮膚炎の臨床試験市場規模、シェア、動向分析レポート：分子タイプ別、試験デザイン別、試験フェーズ別、地域別、セグメント別予測、2024年～2030年

Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report By Molecule Type (Small molecules, Large Molecules), By Study Designs, By Study Phase, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 125 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
アトピー性皮膚炎の臨床試験市場規模、シェア、動向分析レポート：分子タイプ別、試験デザイン別、試験フェーズ別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年01月05日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アトピー性皮膚炎の臨床試験市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のアトピー性皮膚炎の臨床試験市場は2030年までに48億4,000万米ドルに達し、2024年から2030年までのCAGRは11.1％で拡大すると予測されています。

バイオテクノロジーと医学の研究開拓、アトピー性皮膚炎の有病率の増加、製薬企業による新薬開発への投資の増加、CROとスポンサー企業間の提携・買収の増加、臨床研究の技術的進歩、アトピー性皮膚炎製品のパイプラインの増加、臨床試験の世界化などは、予測期間中の世界市場の有利な成長を支える要因の一部です。

製薬企業にとって、技術革新と診療所への容易なアクセスは重要な要素です。さらに、製薬会社やバイオ製薬会社は、アトピー性皮膚炎治療のための新薬開発にますます力を入れるようになっています。例えば、米国FDAは、アトピー性皮膚炎を治療するためのいくつかの潜在的な治療薬が今後数年間で上市されると述べています。市場に参入する可能性のある生物学的製剤には、協和キリンのロカチンリマブ、イーライリリーのレブリキズマブ、キーメッドバイオサイエンスのCM310、アストラゼネカのトゾラキマブなどがあります。したがって、治療薬のパイプラインが増加していることは、市場の成長を増大させる主な要因の1つです。

さらに、アトピー性皮膚炎の有病率の増加がマーケット成長を後押しする重要なカタリストとなっています。アトピー性皮膚炎は慢性の炎症性皮膚疾患であり、世界的に罹患率が顕著に増加しており、あらゆる年齢層の患者が罹患しています。2022年には、Global Burden of Disease（GBD）2022報告書によると、約2億2,300万人がアトピー性皮膚炎と付き合っています。そのうち4,300万人は1歳から4歳の年齢層です。このような有病率の急増は、より効果的で的を絞った治療オプションに対する切実なニーズを生み出しています。その結果、製薬会社、調査機関、ヘルスケア機関は、新たな治療介入を模索するための臨床試験への投資を増やしています。

さらに、複数の企業が業界内での地位を高めるため、M&Aなどの無機的な戦略イニシアチブに注力しています。例えば、2022年3月、ファイザー社は、アトピー性皮膚炎を含む様々な免疫炎症性疾患に対する革新的な潜在的治療法の開発に専念する臨床段階の企業であるアリーナ・ファーマシューティカルズの買収を発表しました。

アトピー性皮膚炎の臨床試験市場レポートハイライト

  • アトピー性皮膚炎臨床試験業界に浸透しつつある生物製剤のパイプライン増加により、2023年の分子タイプ別シェアは大型分子が53.2%で圧倒的。
  • 介入試験デザインによる臨床試験の数が多いため、介入試験が市場を独占。
  • フェーズIIIは2023年に最も高い市場シェアを占めると予想されます。これは、第III相試験を受ける薬剤の数が増加しているためです。さらに、第III相試験のコストは他の相よりもはるかに高く、最大の市場シェアに寄与しています。
  • 北米は、同地域におけるアトピー性皮膚炎の有病率の増加、同地域における大手市場プレイヤーの存在、質の高いヘルスケアに対する政府の支援、償還制度の利用可能性などの要因により、市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アトピー性皮膚炎の臨床試験市場変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • アトピー性皮膚炎の臨床試験市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 アトピー性皮膚炎の臨床試験市場：分子タイプ別の推定・動向分析

  • 分子タイプの市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 分子タイプ別の世界のアトピー性皮膚炎の臨床試験市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 アトピー性皮膚炎の臨床試験市場：研究デザイン別の推定・動向分析

  • 研究デザイン別の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 研究デザイン別の世界のアトピー性皮膚炎の臨床試験市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 アトピー性皮膚炎の臨床試験市場：フェーズ別の推定・動向分析

  • フェーズ別の市場シェア、2023年および2030年
  • セグメントダッシュボード
  • フェーズ別の世界のアトピー性皮膚炎の臨床試験市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第7章 アトピー性皮膚炎の臨床試験市場：地域別の推定・動向分析

  • 地域別の市場シェア分析、2023年および2030年
  • 地域別の市場ダッシュボード
  • 地域別市場のスナップショット
  • 市場規模、予測および動向分析、2018年から2030年まで
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 会社/競合の分類
    • イノベーター
    • マーケットリーダー
    • 新興企業
    • 企業の市場シェア分析、2023年
  • 企業プロファイル
    • Charles River Laboratories
    • Imavita
    • REPROCELL Inc.
    • Oncodesign services
    • BIOCYTOGEN
    • QIMA LTD
    • Novotech
    • Redoxis
    • Syneos Health
    • Hooke Laboratories, LLC
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 4 North America Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 5 North America Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 6 U.S. Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 8 U.S. Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 9 Canada Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 10 Canada Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 11 Canada Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 12 Europe Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 14 Europe Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 15 Europe Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 16 UK Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 17 UK Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 18 UK Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 19 Germany Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 20 Germany Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 21 Germany Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 22 France Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 23 France Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 24 France Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 25 Italy Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 26 Italy Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 27 Italy Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 28 Spain Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 29 Spain Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 30 Spain Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 31 Denmark Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 33 Denmark Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 34 Sweden Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 36 Sweden Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 37 Norway Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 38 Norway Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 39 Norway Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 44 Japan Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 45 Japan Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 46 Japan Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 47 China Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 48 China Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 49 China Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 50 India Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 51 India Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 52 India Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 53 Australia Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 54 Australia Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 55 Australia Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 56 Thailand Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 57 Thailand Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 58 Thailand Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 59 South Korea Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 61 South Korea Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 62 Latin America Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 65 Latin America Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 68 Brazil Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 69 Mexico Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 71 Mexico Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 72 Argentina Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 74 Argentina Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 75 MEA Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 77 MEA Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 78 MEA Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 79 South Africa Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 81 South Africa Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 85 UAE Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 86 UAE Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 87 UAE Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Atopic Dermatitis Clinical Trials market: market outlook
  • Fig. 14 Atopic Dermatitis Clinical Trials competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Atopic Dermatitis Clinical Trials market driver impact
  • Fig. 20 Atopic Dermatitis Clinical Trials market restraint impact
  • Fig. 21 Atopic Dermatitis Clinical Trials market: Molecule Type movement analysis
  • Fig. 22 Atopic Dermatitis Clinical Trials market: Molecule Type outlook and key takeaways
  • Fig. 23 Small molecules market estimates and forecast, 2018 - 2030
  • Fig. 24 Large Molecules market estimates and forecast, 2018 - 2030
  • Fig. 25 Atopic Dermatitis Clinical Trials Market: Study Designs movement Analysis
  • Fig. 26 Atopic Dermatitis Clinical Trials market: Study Designs outlook and key takeaways
  • Fig. 27 Interventional market estimates and forecasts,2018 - 2030
  • Fig. 28 Observational market estimates and forecasts,2018 - 2030
  • Fig. 29 Atopic Dermatitis Clinical Trials Market: Phase movement Analysis
  • Fig. 30 Atopic Dermatitis Clinical Trials market: Phase outlook and key takeaways
  • Fig. 31 Phase I market estimates and forecasts,2018 - 2030
  • Fig. 32 Phase II market estimates and forecasts,2018 - 2030
  • Fig. 33 Phase III market estimates and forecasts,2018 - 2030
  • Fig. 34 Phase IV market estimates and forecasts,2018 - 2030
  • Fig. 35 Global Atopic Dermatitis Clinical Trials market: Regional movement analysis
  • Fig. 36 Global Atopic Dermatitis Clinical Trials market: Regional outlook and key takeaways
  • Fig. 37 Global Atopic Dermatitis Clinical Trials market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America
  • Fig. 45 North America market estimates and forecasts, 2018 - 2030
  • Fig. 46 U.S.
  • Fig. 47 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 48 Canada
  • Fig. 49 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 56 France
  • Fig. 57 France market estimates and forecasts, 2018 - 2030
  • Fig. 58 Italy
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 60 Spain
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 62 Denmark
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 64 Sweden
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 66 Norway
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 68 Asia Pacific
  • Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 70 Japan
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 72 China
  • Fig. 73 China market estimates and forecasts, 2018 - 2030
  • Fig. 74 India
  • Fig. 75 India market estimates and forecasts, 2018 - 2030
  • Fig. 76 Australia
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 78 Thailand
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 80 South Korea
  • Fig. 81 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 82 Latin America
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 84 Brazil
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 86 Mexico
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 88 Argentina
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 90 Middle East and Africa
  • Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Africa
  • Fig. 93 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 Saudi Arabia
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 96 UAE
  • Fig. 97 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 98 Kuwait
  • Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 100 Market share of key market players- Atopic Dermatitis Clinical Trials market
目次
Product Code: GVR-4-68040-182-6

Atopic Dermatitis Clinical Trials Market Growth & Trends:

The global atopic dermatitis clinical trials market is expected to reach USD 4.84 billion by 2030 and expand at a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advancements in biotechnology and medicine, growing prevalence of atopic dermatitis, increasing investments by pharmaceutical companies in the development of novel drugs, rising partnerships and acquisitions among CROs and sponsor companies, technological advancements in clinical research, growing pipeline of atopic dermatitis products, and globalization of clinical trials are few of the factors supporting the lucrative growth of the global market during the forecast period.

For pharmaceutical companies, innovation and easy access to clinics are critical factors. Furthermore, pharmaceutical and biopharmaceutical companies increasingly focus on developing novel drugs for treating atopic dermatitis. For instance, the U.S. FDA stated that several potential therapeutics will be launched in the coming years to treat atopic dermatitis. A few of the potential biologics likely to enter the market include Rocatinlimab by -Kyowa Kirin Co., Ltd., lebrikizumab by Eli Lilly and Company, CM310 by Keymed Biosciences, tozorakimab by AstraZeneca and several others. Hence, the increasing pipeline of therapeutics is one of the major factors augmenting market growth.

Furthermore, the increasing prevalence of atopic dermatitis is a significant catalyst propelling the market growth. Atopic dermatitis is a chronic inflammatory skin condition that has witnessed a notable rise in incidence globally, affecting individuals of all ages. In 2022, approximately 223 million individuals are coping with atopic dermatitis, per the Global Burden of Disease (GBD) 2022 report. Among them, approximately 43 million falls within the age group of 1 to 4 years. This surge in prevalence has created a compelling need for more effective and targeted treatment options. As a result, pharmaceutical companies, research institutions, and healthcare organizations are increasingly investing in clinical trials to explore novel therapeutic interventions.

Moreover, several companies are focusing on inorganic strategic initiatives such as mergers and acquisitions to enhance their position in the industry. For instance, in March 2022, Pfizer Inc. announced the acquisition of Arena Pharmaceuticals, a clinical-stage company dedicated to developing innovative potential therapies for various immuno-inflammatory diseases, including atopic dermatitis.

Atopic Dermatitis Clinical Trials Market Report Highlights:

  • Large molecules dominated the molecule type segment with a 53.2% share in 2023 due to the increasing pipeline of biologics penetrating the atopic dermatitis clinical trials industry.
  • Interventional trials dominated the market owing to the large number of clinical trials with interventional study designs.
  • Phase III category by phase segment is anticipated to hold the highest market share in 2023. This is due to the increasing number of drugs undergoing phase III studies. Moreover, the cost of phase III studies is much higher than the other phases, contributing to the largest market share.
  • North America dominated the market owing to factors such as increasing the prevalence of atopic dermatitis in the region, presence of major market players in the region, government support for quality healthcare, and availability of reimbursement.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Approach 1: Commodity flow approach
    • 1.8.3. Parent Market Analysis (Model 2)
    • 1.8.4. Approach 2: Parent Market Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of atopic dermatitis
      • 3.2.1.2. Growing pipeline of therapeutics
      • 3.2.1.3. Increasing funding and investments
    • 3.2.2. market restraint analysis
      • 3.2.2.1. High cost of clinical trials
      • 3.2.2.2. Issues in patient recruitment and retention
  • 3.3. Atopic Dermatitis Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Clinical Trials Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Molecule Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Atopic Dermatitis Clinical Trials Market by Molecule Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Small molecules
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Large Molecules
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Clinical Trials Market: Study Designs Estimates & Trend Analysis

  • 5.1. Study Designs Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Atopic Dermatitis Clinical Trials Market by Study Designs Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Interventional
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Observational
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. Phase Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Atopic Dermatitis Clinical Trials Market by Phase Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Phase I
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Phase II
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Phase III
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Phase IV
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Thailand
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Charles River Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Imavita
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. REPROCELL Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Oncodesign services
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. BIOCYTOGEN
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. QIMA LTD
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Novotech
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Redoxis
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Syneos Health
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Hooke Laboratories, LLC
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives